An individual participant meta-analysis of mirabegron in multiple sclerosis and spinal cord injury.

Published in: Neurourology and urodynamics (2024)

Our IPDMA provides evidence supporting the use of mirabegron in patients with NLUTD due to SCI or MS. Further work evaluating differential responses in people with different SCI lesion characteristics may be warranted.

Keyphrases

spinal cord injury
multiple sclerosis
systematic review
spinal cord
neuropathic pain
meta analyses
white matter
mass spectrometry
ms ms
case control